Arbutus Biopharma Corporation
ABUS
$3.60
$0.0150.42%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 53.23% | -50.69% | -65.98% | -69.69% | -57.25% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 53.23% | -50.69% | -65.98% | -69.69% | -57.25% |
| Cost of Revenue | -40.25% | -53.18% | -46.26% | -38.85% | -31.30% |
| Gross Profit | 61.53% | 53.74% | 39.82% | 26.79% | 20.28% |
| SG&A Expenses | -7.03% | 18.50% | 14.92% | 4.04% | 23.49% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -35.49% | -20.55% | -16.96% | -15.31% | -5.86% |
| Operating Income | 46.31% | 15.66% | 5.56% | -0.10% | -10.33% |
| Income Before Tax | 29.62% | -2.94% | 4.02% | -1.63% | -5.70% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 29.62% | -2.94% | 4.02% | -1.63% | -5.70% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 29.62% | -2.94% | 4.02% | -1.63% | -5.70% |
| EBIT | 46.31% | 15.66% | 5.56% | -0.10% | -10.33% |
| EBITDA | 46.61% | 15.85% | 5.63% | -0.03% | -10.36% |
| EPS Basic | 35.30% | 7.97% | 13.93% | 8.39% | 4.25% |
| Normalized Basic EPS | 53.02% | 26.10% | 17.02% | 11.81% | 3.22% |
| EPS Diluted | 34.69% | 6.38% | 12.33% | 7.16% | 3.01% |
| Normalized Diluted EPS | 53.02% | 26.10% | 17.02% | 11.81% | 3.22% |
| Average Basic Shares Outstanding | 8.74% | 11.75% | 11.83% | 10.82% | 10.32% |
| Average Diluted Shares Outstanding | 8.87% | 11.75% | 11.83% | 10.82% | 10.32% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |